The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) is a collaborative research network with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations. For the purpose of the funding opportunities that will support this discovery research initiative, cancer prevention is defined as primary prevention of cancer before the oncogenic process begins, while cancer interception refers to disruption of the oncogenic process during the precursor or precancer state or stage. The program focuses on advancing promising efficacious agents to the NCI’s existing R&D pipelines, PREVENT Cancer Preclinical Drug Development Program (PREVENT) and Cancer Prevention Clinical Trials Network (CP-CTNet) for further development, thereby establishing a concerted roadmap for streamlining the drug development process through the gamut of steps from discovery to early phase clinical trials.
Read more About Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
- CAP-IT Specialized Center at Fox Chase Cancer Center
- CAP-IT Specialized Center at Weill Medical College of Cornell University
- Steering Committee - pending
- Coordination center - pending
- NCI Program Contact
News and Information
- Meetings and Workshops
- Articles and Newsletters
- Awards and Accomplishments
- RFA-CA-22-055: Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)
- NOT-CA-23-012: Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
- Can a U54 Center be formed within the same organization?
- Is each U54 Center expected to have an Informatics group?
- For data storage and public dissemination, will these functions be performed by U54 CAP-IT Center?
- And more.